Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MANISH SHARMA

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1790819332
CMS profile
1126262
Location
GRAND RAPIDS, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$659.76

21 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $659.76 21

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MANISH SHARMA

NPI 1790819332 · CMS profile ID 1126262

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

GRAND RAPIDS, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790819332?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MANISH SHARMA, NPI 1790819332, CMS profile ID 1126262. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790819332?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). MANISH SHARMA, NPI 1790819332, CMS profile ID 1126262. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790819332?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
MANISH SHARMA, NPI 1790819332, CMS profile ID 1126262, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1790819332?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

21 matching records · $659.76 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 21 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–21 of 21.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $14.4712/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673686549 CMS
Ipsen Biopharmaceuticals, Inc $17.0710/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 640638413 CMS
AstraZeneca Pharmaceuticals LP $12.8610/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685625159 CMS
Foundation Medicine, Inc. $112.0810/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675551585 CMS
Bayer HealthCare Pharmaceuticals Inc. $16.8908/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628469207 CMS
Foundation Medicine, Inc. $19.2508/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675551583 CMS
Novo Nordisk Inc $13.3408/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704170771 CMS
TESARO, Inc. $13.9207/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675569505 CMS
EMD Serono, Inc. $14.3306/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702993499 CMS
Taiho Oncology, Inc. $19.3906/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679423277 CMS
Takeda Pharmaceuticals U.S.A., Inc. $11.9306/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697397133 CMS
Foundation Medicine, Inc. $128.8005/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675551581 CMS
Novartis Pharmaceuticals Corporation $20.2305/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660098317 CMS
Celgene Corporation $14.3905/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672773265 CMS
Rigel Pharmaceuticals, Inc. $18.3404/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698994097 CMS
Ipsen Biopharmaceuticals, Inc $20.5503/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 640622585 CMS
AstraZeneca Pharmaceuticals LP $13.0802/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685223109 CMS
Amgen Inc. $21.5002/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662682013 CMS
Ipsen Biopharmaceuticals, Inc $125.0402/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 640640819 CMS
Lilly USA, LLC $13.9902/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658005069 CMS
Foundation Medicine, Inc. $18.3102/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675551579 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $659.76 21
PY2020 $185.35 5
PY2021 $23.93 1
PY2022 $558.49 34
PY2023 $1,123.71 47
PY2024 $773.90 11
PY2025 $1,855.50 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $373.20 2
PY2025 Principal investigator $4,235,582.65 823
PY2024 Recipient $4,269.33 9
PY2024 Principal investigator $3,811,534.65 643
PY2023 Recipient $3,810.00 6
PY2023 Principal investigator $3,149,687.09 471
PY2022 Principal investigator $3,302,171.04 339
PY2021 Recipient $7,293.02 4
PY2021 Principal investigator $2,076,760.51 208
PY2020 Recipient $7,900.00 2
PY2020 Principal investigator $1,132,655.23 78
PY2019 Principal investigator $1,305,040.24 61

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

825 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $542.70 12/31/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1 First-in-Human, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABBV-711 as a Monotherapy or in Combination with Budigalimab (ABBV-181) in Adult Subjects with Advanced Squamous Tumors No dispute reported 06/30/2026 1202532737
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1 First-in-Human, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABBV-303, as Monotherapy and in Combination with Budigalimab (ABBV-181), in Adult Subjects with Advanced Solid Tumors No dispute reported 06/30/2026 1202532739
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202532743
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 as Monotherapy and in Combination with Bevacizumab in Adult Subjects with Advanced Solid Tumors No dispute reported 06/30/2026 1202532745
Principal investigator 1 ABBVIE INC. $101.25 12/31/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202532935
Principal investigator 1 ABBVIE INC. $490.05 12/31/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202533945
Principal investigator 1 ABBVIE INC. $2,728.76 12/31/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202533947
Principal investigator 1 ABBVIE INC. $750.00 12/31/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors with Azirkitug (ABBV-514) as a Single Agent and in Combination with Budigalimab or Bevacizumab No dispute reported 06/30/2026 1202534439
Principal investigator 1 PFIZER INC. $1,622.52 12/29/2025 Non-covered Recipient Entity
START Midwest START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228714829
Principal investigator 1 ABBVIE INC. $3,152.25 12/24/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202531848
Principal investigator 1 ABBVIE INC. $3,152.25 12/24/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202531850
Principal investigator 1 ABBVIE INC. $4,233.60 12/24/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202531902
Principal investigator 1 ABBVIE INC. $1,544.40 12/24/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202531926
Principal investigator 1 ABBVIE INC. $2,115.45 12/24/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202531960
Principal investigator 1 ABBVIE INC. $3,152.25 12/24/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202531982
Principal investigator 1 Genmab U.S., Inc. $719.89 12/24/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235935315
Principal investigator 1 ABBVIE INC. $229.50 12/22/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202531580
Principal investigator 1 ABBVIE INC. $229.50 12/22/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202531586
Principal investigator 1 ABBVIE INC. $1,925.00 12/22/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202531594
Principal investigator 1 ABBVIE INC. $2,813.27 12/22/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202531628
Principal investigator 1 ABBVIE INC. $67.50 12/19/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202531500
Principal investigator 1 PFIZER INC. $1,070.00 12/19/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228806704
Principal investigator 1 Stemline Therapeutics Inc. $21,900.00 12/19/2025 Non-covered Recipient Entity
START MIDWEST, LLC
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244134807
Principal investigator 1 Stemline Therapeutics Inc. $1,500.00 12/19/2025 Non-covered Recipient Entity
START MIDWEST, LLC
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244134812
Principal investigator 1 Stemline Therapeutics Inc. $1,100.00 12/19/2025 Non-covered Recipient Entity
START MIDWEST, LLC
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244134816
Principal investigator 1 ABBVIE INC. $935.00 12/18/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202531082
Principal investigator 1 ABBVIE INC. $202.50 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530684
Principal investigator 1 ABBVIE INC. $202.50 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530686
Principal investigator 1 ABBVIE INC. $58.05 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530688
Principal investigator 1 ABBVIE INC. $5,817.15 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530690
Principal investigator 1 ABBVIE INC. $490.05 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530692
Principal investigator 1 ABBVIE INC. $101.25 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530694
Principal investigator 1 ABBVIE INC. $75.60 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530696
Principal investigator 1 ABBVIE INC. $2,338.20 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530698
Principal investigator 1 ABBVIE INC. $54.00 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530702
Principal investigator 1 ABBVIE INC. $1,998.00 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530706
Principal investigator 1 ABBVIE INC. $47.25 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530708
Principal investigator 1 ABBVIE INC. $75.60 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530718
Principal investigator 1 ABBVIE INC. $472.50 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530720
Principal investigator 1 ABBVIE INC. $982.80 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530722
Principal investigator 1 ABBVIE INC. $1,788.75 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530724
Principal investigator 1 ABBVIE INC. $982.80 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530726
Principal investigator 1 ABBVIE INC. $75.60 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530728
Principal investigator 1 ABBVIE INC. $472.50 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530730
Principal investigator 1 ABBVIE INC. $87.75 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530732
Principal investigator 1 ABBVIE INC. $172.80 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530734
Principal investigator 1 ABBVIE INC. $445.50 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530736
Principal investigator 1 ABBVIE INC. $445.50 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530738
Principal investigator 1 ABBVIE INC. $445.50 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530740
Principal investigator 1 ABBVIE INC. $47.25 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530742
Principal investigator 1 ABBVIE INC. $101.25 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530744
Principal investigator 1 ABBVIE INC. $982.80 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530746
Principal investigator 1 ABBVIE INC. $7,425.00 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530748
Principal investigator 1 ABBVIE INC. $101.25 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530750
Principal investigator 1 ABBVIE INC. $101.25 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530752
Principal investigator 1 ABBVIE INC. $445.50 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530754
Principal investigator 1 ABBVIE INC. $75.60 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530756
Principal investigator 1 ABBVIE INC. $67.50 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530758
Principal investigator 1 ABBVIE INC. $87.75 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530760
Principal investigator 1 ABBVIE INC. $101.25 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530762
Principal investigator 1 ABBVIE INC. $101.25 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530764
Principal investigator 1 ABBVIE INC. $202.50 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530766
Principal investigator 1 ABBVIE INC. $982.80 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530768
Principal investigator 1 ABBVIE INC. $75.60 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530770
Principal investigator 1 ABBVIE INC. $7,425.00 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530772
Principal investigator 1 ABBVIE INC. $101.25 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530774
Principal investigator 1 ABBVIE INC. $2,338.20 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530776
Principal investigator 1 ABBVIE INC. $1,788.75 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530778
Principal investigator 1 ABBVIE INC. $7,425.00 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530788
Principal investigator 1 ABBVIE INC. $75.60 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530790
Principal investigator 1 ABBVIE INC. $1,788.75 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530792
Principal investigator 1 ABBVIE INC. $810.00 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530794
Principal investigator 1 ABBVIE INC. $67.50 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530796
Principal investigator 1 ABBVIE INC. $7,425.00 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530798
Principal investigator 1 ABBVIE INC. $445.50 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530800
Principal investigator 1 ABBVIE INC. $101.25 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530802
Principal investigator 1 ABBVIE INC. $1,998.00 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530804
Principal investigator 1 ABBVIE INC. $75.60 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530806
Principal investigator 1 ABBVIE INC. $472.50 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530808
Principal investigator 1 ABBVIE INC. $174.15 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530810
Principal investigator 1 ABBVIE INC. $1,998.00 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530812
Principal investigator 1 ABBVIE INC. $101.25 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530814
Principal investigator 1 ABBVIE INC. $101.25 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530816
Principal investigator 1 ABBVIE INC. $1,788.75 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530818
Principal investigator 1 ABBVIE INC. $49.95 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530820
Principal investigator 1 ABBVIE INC. $183.60 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530822
Principal investigator 1 ABBVIE INC. $472.50 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530824
Principal investigator 1 ABBVIE INC. $490.05 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530826
Principal investigator 1 ABBVIE INC. $101.25 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530828
Principal investigator 1 ABBVIE INC. $445.50 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530830
Principal investigator 1 ABBVIE INC. $810.00 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530836
Principal investigator 1 ABBVIE INC. $1,998.00 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530838
Principal investigator 1 ABBVIE INC. $1,998.00 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530840
Principal investigator 1 ABBVIE INC. $101.25 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530842
Principal investigator 1 ABBVIE INC. $490.05 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530844
Principal investigator 1 ABBVIE INC. $40.50 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530846
Principal investigator 1 ABBVIE INC. $810.00 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530848
Principal investigator 1 ABBVIE INC. $7,425.00 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530850
Principal investigator 1 ABBVIE INC. $810.00 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530852
Principal investigator 1 ABBVIE INC. $445.50 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530854
Principal investigator 1 ABBVIE INC. $490.05 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530856
Principal investigator 1 ABBVIE INC. $117.45 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530858
Principal investigator 1 ABBVIE INC. $75.60 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530860
Principal investigator 1 ABBVIE INC. $72.90 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530862
Principal investigator 1 ABBVIE INC. $75.60 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530864
Principal investigator 1 ABBVIE INC. $2,338.20 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530866
Principal investigator 1 ABBVIE INC. $490.00 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530868
Principal investigator 1 ABBVIE INC. $445.50 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530870
Principal investigator 1 ABBVIE INC. $75.60 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530872
Principal investigator 1 ABBVIE INC. $62.10 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530874
Principal investigator 1 ABBVIE INC. $45.90 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530876
Principal investigator 1 ABBVIE INC. $40.50 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530878
Principal investigator 1 ABBVIE INC. $75.60 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530880
Principal investigator 1 ABBVIE INC. $445.50 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530882
Principal investigator 1 ABBVIE INC. $13,647.27 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530884
Principal investigator 1 ABBVIE INC. $1,788.75 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530886
Principal investigator 1 ABBVIE INC. $810.00 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530888
Principal investigator 1 ABBVIE INC. $101.25 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530890
Principal investigator 1 ABBVIE INC. $101.25 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530892
Principal investigator 1 ABBVIE INC. $101.25 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530894
Principal investigator 1 ABBVIE INC. $2,338.20 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530896
Principal investigator 1 ABBVIE INC. $982.80 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530898
Principal investigator 1 ABBVIE INC. $75.60 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530900
Principal investigator 1 ABBVIE INC. $490.05 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530902
Principal investigator 1 ABBVIE INC. $101.25 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530904
Principal investigator 1 ABBVIE INC. $86.40 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530906
Principal investigator 1 ABBVIE INC. $490.05 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530908
Principal investigator 1 ABBVIE INC. $101.25 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530910
Principal investigator 1 ABBVIE INC. $101.25 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530912
Principal investigator 1 ABBVIE INC. $1,998.00 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530914
Principal investigator 1 ABBVIE INC. $490.05 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530916
Principal investigator 1 ABBVIE INC. $445.50 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530918
Principal investigator 1 ABBVIE INC. $13,647.31 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530920
Principal investigator 1 ABBVIE INC. $472.50 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530922
Principal investigator 1 ABBVIE INC. $1,788.75 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530924
Principal investigator 1 ABBVIE INC. $982.80 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530926
Principal investigator 1 ABBVIE INC. $101.25 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530928
Principal investigator 1 ABBVIE INC. $490.05 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530930
Principal investigator 1 ABBVIE INC. $445.50 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530932
Principal investigator 1 ABBVIE INC. $810.00 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530934
Principal investigator 1 ABBVIE INC. $101.25 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530936
Principal investigator 1 ABBVIE INC. $445.50 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530938
Principal investigator 1 ABBVIE INC. $472.50 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530940
Principal investigator 1 ABBVIE INC. $490.05 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530942
Principal investigator 1 ABBVIE INC. $2,338.20 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530944
Principal investigator 1 ABBVIE INC. $202.50 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530946
Principal investigator 1 ABBVIE INC. $490.10 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530950
Principal investigator 1 ABBVIE INC. $54.00 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530952
Principal investigator 1 ABBVIE INC. $101.25 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530954
Principal investigator 1 ABBVIE INC. $7,425.00 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530956
Principal investigator 1 ABBVIE INC. $101.25 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530958
Principal investigator 1 ABBVIE INC. $2,338.20 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530960
Principal investigator 1 ABBVIE INC. $7,425.00 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530962
Principal investigator 1 ABBVIE INC. $101.25 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530964
Principal investigator 1 Genmab U.S., Inc. $825.00 12/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935526
Principal investigator 1 PFIZER INC. $9,120.14 12/16/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228815695
Principal investigator 1 ABBVIE INC. $935.00 12/15/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530398
Principal investigator 1 ABBVIE INC. $1,005.00 12/15/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530480
Principal investigator 1 ABBVIE INC. $1,135.00 12/15/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202530486
Principal investigator 1 ABBVIE INC. $1,005.00 12/15/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530488
Principal investigator 1 Tanabe Pharma America, Inc. $96,452.83 12/15/2025 Non-covered Recipient Entity
START Midwest, LLC
A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy ofMT-4561in Patients With Various Advanced Solid Tumors and to Evaluate Effect ofMT-4561on Pharmacokinetics of Oral Midazolam No dispute reported 06/30/2026 1243870903
Principal investigator 1 ABBVIE INC. $87.75 12/12/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530324
Principal investigator 1 ABBVIE INC. $5,275.15 12/12/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530326
Principal investigator 1 ABBVIE INC. $445.50 12/12/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530330
Principal investigator 1 ABBVIE INC. $445.50 12/12/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530334
Principal investigator 1 ABBVIE INC. $87.75 12/12/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530340
Principal investigator 1 ABBVIE INC. $445.50 12/12/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530342
Principal investigator 1 ABBVIE INC. $2,250.45 12/12/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202530346
Principal investigator 1 ModernaTX, Inc. $10,195.89 12/12/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors No dispute reported 06/30/2026 1252984900
Principal investigator 1 ABBVIE INC. $3,015.00 12/11/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202529972
Principal investigator 1 ABBVIE INC. $445.50 12/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202529184
Principal investigator 1 ABBVIE INC. $151.20 12/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202529186
Principal investigator 1 ABBVIE INC. $2,338.20 12/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202529188
Principal investigator 1 ABBVIE INC. $1,647.50 12/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202529190
Principal investigator 1 ABBVIE INC. $810.00 12/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202529192
Principal investigator 1 ABBVIE INC. $1,788.75 12/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202529196
Principal investigator 1 ABBVIE INC. $6,007.50 12/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202529198
Principal investigator 1 ABBVIE INC. $467.10 12/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202529200
Principal investigator 1 ABBVIE INC. $1,998.00 12/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202529202
Principal investigator 1 ABBVIE INC. $2,025.00 12/04/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202526428
Principal investigator 1 ABBVIE INC. $54.00 12/04/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202526430
Principal investigator 1 ABBVIE INC. $101.25 12/04/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202526432
Principal investigator 1 ABBVIE INC. $101.25 12/04/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202526436
Principal investigator 1 ABBVIE INC. $202.50 12/04/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202526438
Principal investigator 1 ABBVIE INC. $32.13 12/04/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202526444
Principal investigator 1 ABBVIE INC. $2,058.75 12/04/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202526446
Principal investigator 1 ABBVIE INC. $67.50 12/04/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202526448
Principal investigator 1 ABBVIE INC. $1,200.00 12/04/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202526450
Principal investigator 1 ABBVIE INC. $2,268.00 12/04/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202526454
Principal investigator 1 PFIZER INC. $67,324.13 12/04/2025 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1228815909
Principal investigator 1 ABBVIE INC. $4,549.34 12/03/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202526336
Principal investigator 1 ABBVIE INC. $1,005.00 12/03/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202526338
Principal investigator 1 Genmab U.S., Inc. $6,220.80 12/03/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935530
Principal investigator 1 Genmab U.S., Inc. $16,100.00 12/03/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935550
Principal investigator 1 Genmab U.S., Inc. $12,441.60 12/03/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935557
Principal investigator 1 Genmab U.S., Inc. $21,263.85 12/03/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935564
Principal investigator 1 Genmab U.S., Inc. $6,220.80 12/03/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935576
Principal investigator 1 Genmab U.S., Inc. $400.00 12/03/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935581
Principal investigator 1 Genmab U.S., Inc. $25,034.48 12/03/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935588
Principal investigator 1 Genmab U.S., Inc. $6,220.80 12/03/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935604
Principal investigator 1 Genmab U.S., Inc. $1,200.00 12/03/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935607
Principal investigator 1 Genmab U.S., Inc. $12,441.60 12/03/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935618
Principal investigator 1 Genmab U.S., Inc. $1,264.00 12/03/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935626
Principal investigator 1 Genmab U.S., Inc. $1,121.85 12/03/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935635
Principal investigator 1 Genmab U.S., Inc. $16,100.00 12/03/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935643
Principal investigator 1 Genmab U.S., Inc. $6,220.80 12/03/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935648
Principal investigator 1 PFIZER INC. $1,622.52 12/02/2025 Non-covered Recipient Entity
START Midwest START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228707195
Principal investigator 1 ModernaTX, Inc. $10,180.35 12/01/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors No dispute reported 06/30/2026 1252984908
Principal investigator 1 ABBVIE INC. $445.50 11/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202526038
Principal investigator 1 ABBVIE INC. $445.50 11/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202526040
Principal investigator 1 ABBVIE INC. $2,250.45 11/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202526042
Principal investigator 1 ABBVIE INC. $87.75 11/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202526044
Principal investigator 1 ABBVIE INC. $2,250.45 11/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202526046
Principal investigator 1 ABBVIE INC. $87.75 11/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202526048
Principal investigator 1 ABBVIE INC. $445.50 11/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202526072
Principal investigator 1 ABBVIE INC. $472.50 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525798
Principal investigator 1 ABBVIE INC. $64.26 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525802
Principal investigator 1 ABBVIE INC. $3,500.01 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525804
Principal investigator 1 ABBVIE INC. $32.13 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525806
Principal investigator 1 ABBVIE INC. $32.13 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525808
Principal investigator 1 ABBVIE INC. $7,425.00 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525810
Principal investigator 1 ABBVIE INC. $472.50 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525812
Principal investigator 1 ABBVIE INC. $3,253.50 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525824
Principal investigator 1 ABBVIE INC. $3,152.25 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525826
Principal investigator 1 ABBVIE INC. $2,813.27 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525828
Principal investigator 1 ABBVIE INC. $3,253.50 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525830
Principal investigator 1 ABBVIE INC. $3,253.50 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525832
Principal investigator 1 ABBVIE INC. $3,152.25 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525834
Principal investigator 1 ABBVIE INC. $135.00 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525838
Principal investigator 1 ABBVIE INC. $67.50 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525840
Principal investigator 1 ABBVIE INC. $490.05 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525842
Principal investigator 1 ABBVIE INC. $7,425.00 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525844
Principal investigator 1 ABBVIE INC. $3,711.15 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525846
Principal investigator 1 ABBVIE INC. $67.50 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525848
Principal investigator 1 ABBVIE INC. $32.13 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525850
Principal investigator 1 ABBVIE INC. $4,478.56 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525852
Principal investigator 1 ABBVIE INC. $54.00 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525854
Principal investigator 1 ABBVIE INC. $67.50 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525856
Principal investigator 1 ABBVIE INC. $3,152.25 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525862
Principal investigator 1 ABBVIE INC. $135.00 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525864
Principal investigator 1 ABBVIE INC. $229.50 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525866
Principal investigator 1 ABBVIE INC. $67.50 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525868
Principal investigator 1 ABBVIE INC. $365.85 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525870
Principal investigator 1 ABBVIE INC. $472.50 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525872
Principal investigator 1 ABBVIE INC. $101.25 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525886
Principal investigator 1 ABBVIE INC. $101.25 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525888
Principal investigator 1 ABBVIE INC. $67.50 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525892
Principal investigator 1 ABBVIE INC. $67.50 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525894
Principal investigator 1 ABBVIE INC. $202.50 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525904
Principal investigator 1 ABBVIE INC. $101.25 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525906
Principal investigator 1 ABBVIE INC. $229.50 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525908
Principal investigator 1 ABBVIE INC. $367.00 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525910
Principal investigator 1 ABBVIE INC. $409.05 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202526002
Principal investigator 1 ABBVIE INC. $7,425.00 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202526004
Principal investigator 1 ABBVIE INC. $67.50 11/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202526006
Principal investigator 1 ABBVIE INC. $75.60 11/26/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525412
Principal investigator 1 ABBVIE INC. $75.60 11/26/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525418
Principal investigator 1 ABBVIE INC. $75.60 11/26/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525420
Principal investigator 1 ABBVIE INC. $75.60 11/26/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525422
Principal investigator 1 ABBVIE INC. $75.60 11/26/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525424
Principal investigator 1 ABBVIE INC. $75.60 11/26/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525426
Principal investigator 1 PFIZER INC. $11,715.30 11/26/2025 Non-covered Recipient Entity
START Midwest LLC
AN OPENLABEL PHASE 1 STUDY TO EVALUATE PF08046037 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1228818493
Principal investigator 1 PFIZER INC. $6,696.00 11/26/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228818537
Principal investigator 1 Genmab U.S., Inc. $719.89 11/24/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235935319
Principal investigator 1 PFIZER INC. $1,053.00 11/15/2025 Non-covered Recipient Entity
START Midwest LLC
AN OPENLABEL PHASE 1 STUDY TO EVALUATE PF08046037 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1228818489
Principal investigator 1 AstraZeneca Pharmaceuticals LP $46,500.00 11/14/2025 Non-covered Recipient Entity
START MIDWEST, LLC
A Phase I II Open label Dose Escalation and Expansion Study to Evaluate the Safety Pharmacokinetics Pharmacodynamics and Efficacy of AZD6750 a CD8 Guided IL2 Agent Alone and in Combination With Other Anticancer Agents in Participants with Select Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1185541746
Principal investigator 1 PFIZER INC. $1,206.31 11/14/2025 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1228817910
Principal investigator 1 PFIZER INC. $7,836.75 11/14/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL STUDY OF PF07934040 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING MUTATIONS IN THE KRAS GENE No dispute reported 06/30/2026 1228817959
Principal investigator 1 PFIZER INC. $6,090.22 11/14/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228818481
Principal investigator 1 Tanabe Pharma America, Inc. $14,521.35 11/14/2025 Non-covered Recipient Entity
START Midwest, LLC
A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy ofMT-4561in Patients With Various Advanced Solid Tumors and to Evaluate Effect ofMT-4561on Pharmacokinetics of Oral Midazolam No dispute reported 06/30/2026 1243870901
Principal investigator 1 ABBVIE INC. $55,370.25 11/13/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202524337
Principal investigator 1 Genmab U.S., Inc. $825.00 11/12/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935546
Principal investigator 1 Genmab U.S., Inc. $19,656.01 11/12/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935615
Principal investigator 1 Genmab U.S., Inc. $1,925.00 11/12/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935622
Principal investigator 1 ModernaTX, Inc. $16,166.27 11/12/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors No dispute reported 06/30/2026 1252984902
Principal investigator 1 ModernaTX, Inc. $350.00 11/12/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors No dispute reported 06/30/2026 1252984906
Principal investigator 1 ABBVIE INC. $550.00 11/06/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202523171
Principal investigator 1 ABBVIE INC. $630.00 11/06/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202523177
Principal investigator 1 ABBVIE INC. $1,998.00 11/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202521267
Principal investigator 1 ABBVIE INC. $270.00 11/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202521273
Principal investigator 1 ABBVIE INC. $2,338.20 11/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202521275
Principal investigator 1 ABBVIE INC. $1,788.75 11/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202521277
Principal investigator 1 ABBVIE INC. $2,338.20 11/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202521279
Principal investigator 1 ABBVIE INC. $270.00 11/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202521281
Principal investigator 1 ABBVIE INC. $2,338.20 11/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202521287
Principal investigator 1 ABBVIE INC. $270.00 11/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202521289
Principal investigator 1 ABBVIE INC. $270.00 11/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202521291
Principal investigator 1 ABBVIE INC. $270.00 11/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202521297
Principal investigator 1 ABBVIE INC. $1,998.00 11/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202521299
Principal investigator 1 ABBVIE INC. $270.00 11/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202521301
Principal investigator 1 ABBVIE INC. $1,788.75 11/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202521305
Principal investigator 1 ABBVIE INC. $270.00 11/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202521307
Principal investigator 1 ABBVIE INC. $1,788.75 11/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202521311
Principal investigator 1 ABBVIE INC. $5,817.15 11/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202521313
Principal investigator 1 ABBVIE INC. $270.00 11/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202521315
Principal investigator 1 ABBVIE INC. $1,998.00 11/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202521317
Principal investigator 1 ABBVIE INC. $270.00 11/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202521319
Principal investigator 1 PFIZER INC. $3,393.13 11/05/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228817905
Principal investigator 1 Merck Sharp & Dohme LLC $48,880.00 11/04/2025 Non-covered Recipient Entity
START Midwest, LLC
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX 106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1232931800
Principal investigator 1 PFIZER INC. $40,531.05 11/04/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL STUDY OF PF07934040 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING MUTATIONS IN THE KRAS GENE No dispute reported 06/30/2026 1228817965
Principal investigator 1 PFIZER INC. $6,265.00 11/04/2025 Non-covered Recipient Entity
START Midwest LLC
AN OPENLABEL PHASE 1 STUDY TO EVALUATE PF08046037 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1228818438
Principal investigator 1 PFIZER INC. $25,886.20 11/04/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228818531
Principal investigator 1 PFIZER INC. $1,622.52 11/03/2025 Non-covered Recipient Entity
START Midwest START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228715201
Principal investigator 1 ABBVIE INC. $1,456.65 10/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518899
Principal investigator 1 ABBVIE INC. $1,456.65 10/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518955
Principal investigator 1 ABBVIE INC. $1,456.65 10/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519005
Principal investigator 1 ABBVIE INC. $2,060.10 10/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519041
Principal investigator 1 ABBVIE INC. $2,060.10 10/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519043
Principal investigator 1 ABBVIE INC. $2,060.10 10/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519119
Principal investigator 1 ABBVIE INC. $1,456.65 10/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519319
Principal investigator 1 ABBVIE INC. $1,456.65 10/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519355
Principal investigator 1 ABBVIE INC. $3,152.25 10/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519357
Principal investigator 1 ABBVIE INC. $2,060.10 10/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519411
Principal investigator 1 ABBVIE INC. $1,456.65 10/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519449
Principal investigator 1 ABBVIE INC. $2,060.10 10/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519455
Principal investigator 1 ABBVIE INC. $2,060.10 10/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519471
Principal investigator 1 ABBVIE INC. $3,152.25 10/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519481
Principal investigator 1 ABBVIE INC. $364.50 10/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518497
Principal investigator 1 ABBVIE INC. $364.50 10/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518501
Principal investigator 1 ABBVIE INC. $229.50 10/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518503
Principal investigator 1 ABBVIE INC. $351.21 10/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518581
Principal investigator 1 ABBVIE INC. $244.35 10/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518649
Principal investigator 1 Genmab U.S., Inc. $719.89 10/23/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235935311
Principal investigator 1 Genmab U.S., Inc. $25,034.40 10/23/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935568
Principal investigator 1 Genmab U.S., Inc. $7,250.85 10/23/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935592
Principal investigator 1 Genmab U.S., Inc. $12,517.20 10/23/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935611
Principal investigator 1 ABBVIE INC. $2,250.45 10/22/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517733
Principal investigator 1 ABBVIE INC. $2,351.70 10/22/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517735
Principal investigator 1 ABBVIE INC. $1,776.60 10/22/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517745
Principal investigator 1 ABBVIE INC. $2,351.70 10/22/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517747
Principal investigator 1 ABBVIE INC. $3,354.75 10/22/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517749
Principal investigator 1 ABBVIE INC. $3,354.75 10/22/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517751
Principal investigator 1 ABBVIE INC. $2,250.45 10/22/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517765
Principal investigator 1 ABBVIE INC. $2,250.45 10/22/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517789
Principal investigator 1 ABBVIE INC. $2,351.70 10/22/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517809
Principal investigator 1 ABBVIE INC. $3,354.75 10/22/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517819
Principal investigator 1 ABBVIE INC. $1,776.60 10/22/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517827
Principal investigator 1 ABBVIE INC. $1,776.60 10/22/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517841
Principal investigator 1 ABBVIE INC. $2,351.70 10/22/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517843
Principal investigator 1 ABBVIE INC. $3,354.75 10/22/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517987
Principal investigator 1 ABBVIE INC. $3,354.75 10/22/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517989
Principal investigator 1 ABBVIE INC. $2,351.70 10/22/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517991
Principal investigator 1 ABBVIE INC. $1,776.60 10/22/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518015
Principal investigator 1 ABBVIE INC. $2,250.45 10/22/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518017
Principal investigator 1 ABBVIE INC. $2,351.70 10/22/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518019
Principal investigator 1 ABBVIE INC. $3,354.75 10/22/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518021
Principal investigator 1 ABBVIE INC. $1,776.60 10/22/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518031
Principal investigator 1 PFIZER INC. $584.55 10/16/2025 Non-covered Recipient Entity
START Midwest LLC
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228825227
Principal investigator 1 ABBVIE INC. $62,492.85 10/15/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202517071
Principal investigator 1 ModernaTX, Inc. $12,028.51 10/15/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors No dispute reported 06/30/2026 1252984910
Principal investigator 1 PFIZER INC. $4,642.42 10/15/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228825480
Principal investigator 1 PFIZER INC. $6,912.00 10/15/2025 Non-covered Recipient Entity
START Midwest LLC
AN OPENLABEL PHASE 1 STUDY TO EVALUATE PF08046037 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1228826143
Principal investigator 1 Tanabe Pharma America, Inc. $50,535.90 10/15/2025 Non-covered Recipient Entity
START Midwest, LLC
A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy ofMT-4561in Patients With Various Advanced Solid Tumors and to Evaluate Effect ofMT-4561on Pharmacokinetics of Oral Midazolam No dispute reported 06/30/2026 1243870899
Principal investigator 1 ABBVIE INC. $2,274.67 10/13/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202516589
Principal investigator 1 ABBVIE INC. $500.00 10/13/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202516591
Principal investigator 1 ABBVIE INC. $609.00 10/09/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202516491
Principal investigator 1 PFIZER INC. $10,352.41 10/09/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228826071
Principal investigator 1 PFIZER INC. $5,800.00 10/08/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228824361
Principal investigator 1 PFIZER INC. $1,622.52 10/06/2025 Non-covered Recipient Entity
START Midwest START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228715203
Principal investigator 1 ABBVIE INC. $2,813.27 09/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512572
Principal investigator 1 ABBVIE INC. $4,657.50 09/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512598
Principal investigator 1 ABBVIE INC. $364.50 09/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512610
Principal investigator 1 ABBVIE INC. $4,657.50 09/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512708
Principal investigator 1 ABBVIE INC. $30,551.85 09/26/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202512540
Principal investigator 1 PFIZER INC. $65.00 09/26/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228836335
Principal investigator 1 ABBVIE INC. $2,274.67 09/24/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202511974
Principal investigator 1 ABBVIE INC. $1,684.94 09/24/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512042
Principal investigator 1 ABBVIE INC. $2,274.67 09/24/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512044
Principal investigator 1 ABBVIE INC. $2,274.67 09/24/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512046
Principal investigator 1 PFIZER INC. $3,545.00 09/24/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228835341
Principal investigator 1 PFIZER INC. $13,293.22 09/24/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228836706
Principal investigator 1 Genmab U.S., Inc. $385.00 09/23/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935492
Principal investigator 1 ModernaTX, Inc. $4,241.03 09/19/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS LLC
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors No dispute reported 06/30/2026 1252984914
Principal investigator 1 PFIZER INC. $15.00 09/19/2025 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228714038
Principal investigator 1 ABBVIE INC. $500.00 09/17/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202511140
Principal investigator 1 Stemline Therapeutics Inc. $10,577.25 09/17/2025 Non-covered Recipient Entity
START MIDWEST, LLC
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244134800
Principal investigator 1 Stemline Therapeutics Inc. $715.50 09/17/2025 Non-covered Recipient Entity
START MIDWEST, LLC
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244134803
Principal investigator 1 ABBVIE INC. $3,680.10 09/16/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202511118
Principal investigator 1 PFIZER INC. $4,406.41 09/16/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228836317
Principal investigator 1 PFIZER INC. $4,184.33 09/16/2025 Non-covered Recipient Entity
START Midwest LLC
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228836817
Principal investigator 1 PFIZER INC. $12,638.65 09/16/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228836891
Principal investigator 1 ABBVIE INC. $790.00 09/15/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202510946
Principal investigator 1 Genmab U.S., Inc. $4,403.70 09/15/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935510
Principal investigator 1 Tanabe Pharma America, Inc. $139,771.72 09/15/2025 Non-covered Recipient Entity
START Midwest, LLC
A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy ofMT-4561in Patients With Various Advanced Solid Tumors and to Evaluate Effect ofMT-4561on Pharmacokinetics of Oral Midazolam No dispute reported 06/30/2026 1243870897
Principal investigator 1 ABBVIE INC. $30,138.75 09/12/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202510866
Principal investigator 1 ABBVIE INC. $12,958.65 09/12/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202510868
Principal investigator 1 Genmab U.S., Inc. $12,517.20 09/09/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935506
Principal investigator 1 PFIZER INC. $1,857.60 09/09/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL STUDY OF PF07934040 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING MUTATIONS IN THE KRAS GENE No dispute reported 06/30/2026 1228835295
Principal investigator 1 Genmab U.S., Inc. $4,504.95 09/08/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935480
Principal investigator 1 PFIZER INC. $1,622.52 09/08/2025 Non-covered Recipient Entity
START Midwest START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228714831
Principal investigator 1 ABBVIE INC. $1,020.00 09/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202510144
Principal investigator 1 PFIZER INC. $6,583.95 09/03/2025 Non-covered Recipient Entity
START Midwest LLC
AN OPENLABEL PHASE 1 STUDY TO EVALUATE PF08046037 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1228836713
Principal investigator 1 ABBVIE INC. $21,100.00 09/02/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202507023
Principal investigator 1 ABBVIE INC. $2,250.45 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506579
Principal investigator 1 ABBVIE INC. $4,657.50 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506581
Principal investigator 1 ABBVIE INC. $2,250.45 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506583
Principal investigator 1 ABBVIE INC. $522.18 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506585
Principal investigator 1 ABBVIE INC. $457.89 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506587
Principal investigator 1 ABBVIE INC. $159.37 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506589
Principal investigator 1 ABBVIE INC. $98.62 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506591
Principal investigator 1 ABBVIE INC. $2,408.27 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506593
Principal investigator 1 ABBVIE INC. $128.25 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506595
Principal investigator 1 ABBVIE INC. $2,813.27 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506609
Principal investigator 1 ABBVIE INC. $986.71 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506611
Principal investigator 1 ABBVIE INC. $2,408.27 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506613
Principal investigator 1 ABBVIE INC. $55.35 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506623
Principal investigator 1 ABBVIE INC. $4,233.60 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506625
Principal investigator 1 ABBVIE INC. $98.62 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506627
Principal investigator 1 ABBVIE INC. $98.62 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506629
Principal investigator 1 ABBVIE INC. $140.40 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506631
Principal investigator 1 ABBVIE INC. $162.21 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506633
Principal investigator 1 ABBVIE INC. $67.71 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506635
Principal investigator 1 ABBVIE INC. $2,408.27 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506637
Principal investigator 1 ABBVIE INC. $4,657.50 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506659
Principal investigator 1 ABBVIE INC. $4,233.60 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506661
Principal investigator 1 ABBVIE INC. $1,544.40 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506663
Principal investigator 1 ABBVIE INC. $3,253.50 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506665
Principal investigator 1 ABBVIE INC. $140.40 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506667
Principal investigator 1 ABBVIE INC. $140.40 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506679
Principal investigator 1 ABBVIE INC. $519.08 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506681
Principal investigator 1 ABBVIE INC. $364.50 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506683
Principal investigator 1 ABBVIE INC. $140.40 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506699
Principal investigator 1 ABBVIE INC. $162.21 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506701
Principal investigator 1 ABBVIE INC. $1,080.21 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506703
Principal investigator 1 ABBVIE INC. $72.00 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506705
Principal investigator 1 ABBVIE INC. $128.25 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506707
Principal investigator 1 ABBVIE INC. $98.62 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506709
Principal investigator 1 ABBVIE INC. $140.40 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506713
Principal investigator 1 ABBVIE INC. $162.21 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506715
Principal investigator 1 ABBVIE INC. $159.37 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506717
Principal investigator 1 ABBVIE INC. $1,544.40 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506719
Principal investigator 1 ABBVIE INC. $128.25 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506721
Principal investigator 1 ABBVIE INC. $696.60 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506723
Principal investigator 1 ABBVIE INC. $67.71 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506725
Principal investigator 1 ABBVIE INC. $229.50 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506805
Principal investigator 1 ABBVIE INC. $67.71 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506807
Principal investigator 1 ABBVIE INC. $472.71 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506809
Principal investigator 1 ABBVIE INC. $472.71 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506811
Principal investigator 1 ABBVIE INC. $4,657.50 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506813
Principal investigator 1 ABBVIE INC. $2,408.27 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506815
Principal investigator 1 ABBVIE INC. $499.50 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506833
Principal investigator 1 ABBVIE INC. $128.25 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506835
Principal investigator 1 ABBVIE INC. $457.89 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506837
Principal investigator 1 ABBVIE INC. $4,657.50 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506839
Principal investigator 1 ABBVIE INC. $67.71 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506843
Principal investigator 1 ABBVIE INC. $2,813.27 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506845
Principal investigator 1 ABBVIE INC. $1,544.40 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506861
Principal investigator 1 ABBVIE INC. $4,233.60 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506863
Principal investigator 1 ABBVIE INC. $1,544.40 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506865
Principal investigator 1 ABBVIE INC. $1,544.40 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506867
Principal investigator 1 ABBVIE INC. $140.40 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506869
Principal investigator 1 ABBVIE INC. $98.62 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506871
Principal investigator 1 ABBVIE INC. $1,544.40 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506873
Principal investigator 1 ABBVIE INC. $4,233.60 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506875
Principal investigator 1 ABBVIE INC. $4,233.60 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506877
Principal investigator 1 ABBVIE INC. $4,233.60 09/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506879
Principal investigator 1 ABBVIE INC. $1,764.00 08/31/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202506577
Principal investigator 1 ABBVIE INC. $13,230.00 08/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506531
Principal investigator 1 ABBVIE INC. $710.00 08/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506533
Principal investigator 1 ABBVIE INC. $1,788.75 08/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506535
Principal investigator 1 ABBVIE INC. $5,817.15 08/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506537
Principal investigator 1 ABBVIE INC. $2,338.20 08/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506539
Principal investigator 1 ABBVIE INC. $934.20 08/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506569
Principal investigator 1 ABBVIE INC. $1,998.00 08/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506571
Principal investigator 1 ABBVIE INC. $1,788.75 08/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506275
Principal investigator 1 ABBVIE INC. $270.00 08/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506277
Principal investigator 1 ABBVIE INC. $270.00 08/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506279
Principal investigator 1 ABBVIE INC. $1,998.00 08/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506291
Principal investigator 1 ABBVIE INC. $270.00 08/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506303
Principal investigator 1 ABBVIE INC. $270.00 08/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506305
Principal investigator 1 ABBVIE INC. $1,998.00 08/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506307
Principal investigator 1 ABBVIE INC. $1,788.75 08/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506309
Principal investigator 1 ABBVIE INC. $2,338.20 08/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506311
Principal investigator 1 ABBVIE INC. $2,338.20 08/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506317
Principal investigator 1 ABBVIE INC. $270.00 08/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506489
Principal investigator 1 ABBVIE INC. $270.00 08/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506495
Principal investigator 1 Ipsen Pharma SAS $5,575.50 08/28/2025 Non-covered Recipient Entity
Cancer And Hematology Centers Of Western Michigan, Pc
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304921
Principal investigator 1 PFIZER INC. $61,551.91 08/27/2025 Non-covered Recipient Entity
START Midwest LLC
AN OPENLABEL PHASE 1 STUDY TO EVALUATE PF08046037 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1228841313
Principal investigator 1 PFIZER INC. $191.03 08/23/2025 Non-covered Recipient Entity
START Midwest LLC
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228841283
Principal investigator 1 ABBVIE INC. $4,233.60 08/22/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202505587
Principal investigator 1 ModernaTX, Inc. $13,212.46 08/22/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS LLC
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors No dispute reported 06/30/2026 1252984912
Principal investigator 1 PFIZER INC. $4,530.60 08/22/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL STUDY OF PF07934040 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING MUTATIONS IN THE KRAS GENE No dispute reported 06/30/2026 1228842644
Principal investigator 1 ABBVIE INC. $80,493.71 08/20/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202505199
Principal investigator 1 Genmab U.S., Inc. $5,723.19 08/18/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935502
Principal investigator 1 PFIZER INC. $2,740.41 08/14/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228841319
Principal investigator 1 PFIZER INC. $4,642.42 08/14/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228841981
Principal investigator 1 Genmab U.S., Inc. $4,163.40 08/11/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935467
Principal investigator 1 PFIZER INC. $1,622.52 08/11/2025 Non-covered Recipient Entity
START Midwest START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228707111
Principal investigator 1 ABBVIE INC. $3,152.25 08/07/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202503725
Principal investigator 1 ABBVIE INC. $3,152.25 08/07/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202503787
Principal investigator 1 ABBVIE INC. $3,711.15 08/07/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202503789
Principal investigator 1 ABBVIE INC. $3,152.25 08/07/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202503791
Principal investigator 1 ABBVIE INC. $3,152.25 08/07/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202503989
Principal investigator 1 PFIZER INC. $3,668.00 08/05/2025 Non-covered Recipient Entity
START Midwest LLC
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228841307
Principal investigator 1 PFIZER INC. $952.00 08/02/2025 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1228841393
Principal investigator 1 PFIZER INC. $910.00 08/02/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL STUDY OF PF07934040 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING MUTATIONS IN THE KRAS GENE No dispute reported 06/30/2026 1228842637
Principal investigator 1 ABBVIE INC. $440.00 08/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202500894
Principal investigator 1 ABBVIE INC. $365.85 07/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202499894
Principal investigator 1 Ipsen Pharma SAS $10,233.00 07/28/2025 Non-covered Recipient Entity
Cancer And Hematology Centers Of Western Michigan, Pc
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304907
Principal investigator 1 Ipsen Pharma SAS $5,136.75 07/28/2025 Non-covered Recipient Entity
Cancer And Hematology Centers Of Western Michigan, Pc
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304909
Principal investigator 1 Ipsen Pharma SAS $6,582.60 07/28/2025 Non-covered Recipient Entity
Cancer And Hematology Centers Of Western Michigan, Pc
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304911
Principal investigator 1 Ipsen Pharma SAS $6,660.90 07/28/2025 Non-covered Recipient Entity
Cancer And Hematology Centers Of Western Michigan, Pc
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304913
Principal investigator 1 Ipsen Pharma SAS $10,233.00 07/28/2025 Non-covered Recipient Entity
Cancer And Hematology Centers Of Western Michigan, Pc
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304915
Principal investigator 1 Ipsen Pharma SAS $5,136.75 07/28/2025 Non-covered Recipient Entity
Cancer And Hematology Centers Of Western Michigan, Pc
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304917
Principal investigator 1 Ipsen Pharma SAS $6,582.60 07/28/2025 Non-covered Recipient Entity
Cancer And Hematology Centers Of Western Michigan, Pc
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304919
Principal investigator 1 PFIZER INC. $7,375.05 07/26/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL STUDY OF PF07934040 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING MUTATIONS IN THE KRAS GENE No dispute reported 06/30/2026 1228844812
Principal investigator 1 PFIZER INC. $65.00 07/25/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228848534
Principal investigator 1 PFIZER INC. $4,642.42 07/25/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228848540
Principal investigator 1 ABBVIE INC. $17,811.90 07/23/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202499416
Principal investigator 1 PFIZER INC. $45.00 07/22/2025 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228707025
Principal investigator 1 PFIZER INC. $1,622.52 07/22/2025 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228707199
Principal investigator 1 ABBVIE INC. $18,118.73 07/21/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202498978
Principal investigator 1 ABBVIE INC. $20,393.40 07/21/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202498980
Principal investigator 1 ABBVIE INC. $13,186.45 07/21/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202498994
Principal investigator 1 ABBVIE INC. $12,453.59 07/21/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202498996
Principal investigator 1 Genmab U.S., Inc. $5,723.19 07/21/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935471
Principal investigator 1 ABBVIE INC. $2,058.75 07/18/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202498836
Principal investigator 1 ABBVIE INC. $2,608.20 07/18/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202498838
Principal investigator 1 ABBVIE INC. $6,007.50 07/18/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202498850
Principal investigator 1 ABBVIE INC. $467.10 07/18/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202498854
Principal investigator 1 ABBVIE INC. $2,268.00 07/18/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202498868
Principal investigator 1 ModernaTX, Inc. $8,147.93 07/18/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS LLC
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors No dispute reported 06/30/2026 1252984916
Principal investigator 1 Stemline Therapeutics Inc. $7,916.40 07/16/2025 Non-covered Recipient Entity
START MIDWEST, LLC
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244134752
Principal investigator 1 Stemline Therapeutics Inc. $14,037.30 07/16/2025 Non-covered Recipient Entity
START MIDWEST, LLC
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244134757
Principal investigator 1 Stemline Therapeutics Inc. $3,167.10 07/16/2025 Non-covered Recipient Entity
START MIDWEST, LLC
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244134761
Principal investigator 1 Stemline Therapeutics Inc. $4,869.45 07/16/2025 Non-covered Recipient Entity
START MIDWEST, LLC
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244134765
Principal investigator 1 Stemline Therapeutics Inc. $5,128.65 07/16/2025 Non-covered Recipient Entity
START MIDWEST, LLC
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244134769
Principal investigator 1 Stemline Therapeutics Inc. $5,751.00 07/16/2025 Non-covered Recipient Entity
START MIDWEST, LLC
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244134773
Principal investigator 1 Stemline Therapeutics Inc. $5,134.05 07/16/2025 Non-covered Recipient Entity
START MIDWEST, LLC
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244134777
Principal investigator 1 Stemline Therapeutics Inc. $1,502.55 07/16/2025 Non-covered Recipient Entity
START MIDWEST, LLC
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244134780
Principal investigator 1 Stemline Therapeutics Inc. $4,475.25 07/16/2025 Non-covered Recipient Entity
START MIDWEST, LLC
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244134784
Principal investigator 1 Stemline Therapeutics Inc. $4,637.25 07/16/2025 Non-covered Recipient Entity
START MIDWEST, LLC
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244134788
Principal investigator 1 Stemline Therapeutics Inc. $9,127.35 07/16/2025 Non-covered Recipient Entity
START MIDWEST, LLC
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244134791
Principal investigator 1 Stemline Therapeutics Inc. $3,026.70 07/16/2025 Non-covered Recipient Entity
START MIDWEST, LLC
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244134796
Principal investigator 1 PFIZER INC. $1,622.52 07/14/2025 Non-covered Recipient Entity
START Midwest START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228707197
Principal investigator 1 PFIZER INC. $28,992.60 07/11/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL STUDY OF PF07934040 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING MUTATIONS IN THE KRAS GENE No dispute reported 06/30/2026 1228844750
Principal investigator 1 PFIZER INC. $2,618.00 07/11/2025 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1228848513
Principal investigator 1 ABBVIE INC. $255.00 07/09/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202497528
Principal investigator 1 ABBVIE INC. $500.00 07/04/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202496877
Principal investigator 1 ABBVIE INC. $72,449.06 07/03/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202496743
Principal investigator 1 ABBVIE INC. $16,638.75 07/02/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202496735
Principal investigator 1 ABBVIE INC. $38,534.40 07/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202493887
Principal investigator 1 Genmab U.S., Inc. $4,504.95 07/01/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935489
Principal investigator 1 PFIZER INC. $1,996.65 07/01/2025 Non-covered Recipient Entity
START Midwest LLC
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228848502
Principal investigator 1 ABBVIE INC. $85,882.19 06/30/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493655
Principal investigator 1 ABBVIE INC. $65,664.36 06/30/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493665
Principal investigator 1 ABBVIE INC. $270.00 06/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493425
Principal investigator 1 ABBVIE INC. $270.00 06/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493439
Principal investigator 1 ABBVIE INC. $1,998.00 06/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493441
Principal investigator 1 ABBVIE INC. $3,152.25 06/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493443
Principal investigator 1 ABBVIE INC. $270.00 06/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493447
Principal investigator 1 ABBVIE INC. $3,711.15 06/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493449
Principal investigator 1 ABBVIE INC. $1,788.75 06/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493451
Principal investigator 1 ABBVIE INC. $2,338.20 06/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493465
Principal investigator 1 ABBVIE INC. $2,115.45 06/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493467
Principal investigator 1 PFIZER INC. $2,740.41 06/27/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228851460
Principal investigator 1 ABBVIE INC. $2,813.27 06/26/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202492973
Principal investigator 1 ABBVIE INC. $2,589.84 06/26/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202492999
Principal investigator 1 ABBVIE INC. $2,157.84 06/26/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493021
Principal investigator 1 ABBVIE INC. $2,157.84 06/26/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493025
Principal investigator 1 ABBVIE INC. $2,813.27 06/26/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493045
Principal investigator 1 PFIZER INC. $4,642.42 06/26/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228851452
Principal investigator 1 PFIZER INC. $25,616.10 06/26/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228851542
Principal investigator 1 Genmab U.S., Inc. $55.00 06/24/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235935092
Principal investigator 1 Genmab U.S., Inc. $55.00 06/24/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235935145
Principal investigator 1 PFIZER INC. $15.00 06/23/2025 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840173
Principal investigator 1 PFIZER INC. $3,245.02 06/23/2025 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840246
Principal investigator 1 Genmab U.S., Inc. $190.00 06/20/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935476
Principal investigator 1 Genmab U.S., Inc. $380.00 06/20/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935495
Principal investigator 1 ModernaTX, Inc. $3,328.43 06/20/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS LLC
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors No dispute reported 06/30/2026 1252984918
Principal investigator 1 ABBVIE INC. $50.00 06/18/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202491945
Principal investigator 1 ABBVIE INC. $1,750.00 06/16/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202491523
Principal investigator 1 ABBVIE INC. $250.00 06/16/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202491533
Principal investigator 1 ABBVIE INC. $1,788.75 06/16/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202491539
Principal investigator 1 ABBVIE INC. $270.00 06/16/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202491541
Principal investigator 1 ABBVIE INC. $750.00 06/16/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202491579
Principal investigator 1 ABBVIE INC. $5,817.15 06/16/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202491641
Principal investigator 1 ABBVIE INC. $4,749.17 06/16/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202491645
Principal investigator 1 ABBVIE INC. $270.00 06/16/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202491647
Principal investigator 1 ABBVIE INC. $1,998.00 06/16/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202491649
Principal investigator 1 ABBVIE INC. $500.00 06/16/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202491653
Principal investigator 1 ABBVIE INC. $5,817.15 06/16/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202491655
Principal investigator 1 ABBVIE INC. $825.00 06/16/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202491657
Principal investigator 1 ABBVIE INC. $270.00 06/16/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202491661
Principal investigator 1 ABBVIE INC. $2,338.20 06/16/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202491663
Principal investigator 1 PFIZER INC. $1,622.51 06/16/2025 Non-covered Recipient Entity
START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840867
Principal investigator 1 ABBVIE INC. $18,069.75 06/13/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202491457
Principal investigator 1 Genmab U.S., Inc. $450.00 06/13/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235935102
Principal investigator 1 Genmab U.S., Inc. $300.00 06/13/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235935111
Principal investigator 1 Genmab U.S., Inc. $200.00 06/13/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235935114
Principal investigator 1 Genmab U.S., Inc. $400.00 06/13/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235935120
Principal investigator 1 Genmab U.S., Inc. $150.00 06/13/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235935127
Principal investigator 1 Genmab U.S., Inc. $220.00 06/13/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235935136
Principal investigator 1 Genmab U.S., Inc. $400.00 06/13/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235935140
Principal investigator 1 Genmab U.S., Inc. $1,000.00 06/13/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235935155
Principal investigator 1 Genmab U.S., Inc. $4,163.40 06/09/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935484
Principal investigator 1 Genmab U.S., Inc. $900.00 06/05/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235935077
Principal investigator 1 Genmab U.S., Inc. $650.00 06/05/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235935081
Principal investigator 1 Genmab U.S., Inc. $550.00 06/05/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235935084
Principal investigator 1 Genmab U.S., Inc. $600.00 06/05/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235935088
Principal investigator 1 Genmab U.S., Inc. $450.00 06/05/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235935099
Principal investigator 1 Genmab U.S., Inc. $400.00 06/05/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235935106
Principal investigator 1 Genmab U.S., Inc. $750.00 06/05/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235935117
Principal investigator 1 Genmab U.S., Inc. $200.00 06/05/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235935124
Principal investigator 1 Genmab U.S., Inc. $200.00 06/05/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235935132
Principal investigator 1 ModernaTX, Inc. $9,504.01 06/04/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS LLC
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors No dispute reported 06/30/2026 1252984898
Principal investigator 1 ModernaTX, Inc. $2,992.95 06/04/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS LLC
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors No dispute reported 06/30/2026 1252984920
Principal investigator 1 ABBVIE INC. $1,788.75 06/02/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202487177
Principal investigator 1 ABBVIE INC. $1,277.10 06/02/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202487179
Principal investigator 1 ABBVIE INC. $1,998.00 06/02/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202487195
Principal investigator 1 ABBVIE INC. $1,080.00 06/02/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202487203
Principal investigator 1 ABBVIE INC. $8,672.40 06/02/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202487219
Principal investigator 1 ABBVIE INC. $6,007.50 06/02/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202487221
Principal investigator 1 ABBVIE INC. $540.00 06/02/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202487235
Principal investigator 1 ABBVIE INC. $1,788.75 06/02/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202487237
Principal investigator 1 ABBVIE INC. $2,338.20 06/02/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202487241
Principal investigator 1 ABBVIE INC. $26,345.51 06/02/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202487245
Principal investigator 1 ABBVIE INC. $4,336.20 06/02/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202487247
Principal investigator 1 ABBVIE INC. $1,788.75 06/02/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202487249
Principal investigator 1 ABBVIE INC. $1,788.75 06/02/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202487251
Principal investigator 1 ModernaTX, Inc. $47,490.00 06/02/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS LLC
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors No dispute reported 06/30/2026 1252984904
Recipient ABBVIE INC. $43.20 05/30/2025 Covered Recipient Physician Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202401317
Principal investigator 1 ABBVIE INC. $3,000.00 05/30/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202487111
Principal investigator 1 PFIZER INC. $1,965.00 05/30/2025 Non-covered Recipient Entity
START Midwest LLC
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228855236
Principal investigator 1 PFIZER INC. $15,089.23 05/30/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228855361
Principal investigator 1 PFIZER INC. $40,683.00 05/30/2025 Non-covered Recipient Entity
START Midwest LLC
AN OPENLABEL PHASE 1 STUDY TO EVALUATE PF08046037 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1228855636
Principal investigator 1 ABBVIE INC. $2,813.27 05/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202486355
Principal investigator 1 ABBVIE INC. $364.50 05/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202486357
Principal investigator 1 ABBVIE INC. $2,813.27 05/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202486359
Principal investigator 1 ABBVIE INC. $126.00 05/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202486365
Principal investigator 1 ABBVIE INC. $126.00 05/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202486367
Principal investigator 1 ABBVIE INC. $2,589.84 05/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202486369
Principal investigator 1 ABBVIE INC. $364.50 05/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202486371
Principal investigator 1 ABBVIE INC. $126.00 05/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202486395
Principal investigator 1 ABBVIE INC. $11,357.00 05/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202486551
Principal investigator 1 Genmab U.S., Inc. $5,723.19 05/26/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935498
Principal investigator 1 ABBVIE INC. $27,193.64 05/23/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202486071
Principal investigator 1 ABBVIE INC. $2,266.00 05/23/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202486083
Principal investigator 1 PFIZER INC. $6,700.05 05/23/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228855310
Principal investigator 1 PFIZER INC. $40,223.14 05/23/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228856916
Principal investigator 1 ABBVIE INC. $1,788.75 05/21/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202485531
Principal investigator 1 ABBVIE INC. $4,267.84 05/21/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202485533
Principal investigator 1 ABBVIE INC. $500.00 05/21/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202485539
Principal investigator 1 ABBVIE INC. $5,000.00 05/21/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202485541
Principal investigator 1 ABBVIE INC. $6,401.75 05/21/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202485543
Principal investigator 1 ABBVIE INC. $2,133.92 05/21/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202485545
Principal investigator 1 ABBVIE INC. $6,401.75 05/21/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202485547
Principal investigator 1 ABBVIE INC. $270.00 05/21/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202485549
Principal investigator 1 ABBVIE INC. $255.00 05/21/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202485551
Principal investigator 1 ABBVIE INC. $2,133.92 05/21/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202485557
Principal investigator 1 ABBVIE INC. $255.00 05/21/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202485561
Principal investigator 1 ABBVIE INC. $67.50 05/21/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202485563
Principal investigator 1 ABBVIE INC. $67.50 05/21/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202485565
Principal investigator 1 ABBVIE INC. $790.00 05/21/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202485567
Principal investigator 1 ABBVIE INC. $3,085.00 05/21/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202485577
Principal investigator 1 ABBVIE INC. $510.00 05/21/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202485597
Principal investigator 1 ABBVIE INC. $23,383.35 05/21/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202485693
Principal investigator 1 ABBVIE INC. $19,597.95 05/21/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202485695
Principal investigator 1 ABBVIE INC. $2,133.92 05/19/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202485399
Principal investigator 1 Ipsen Pharma SAS $4,000.00 05/19/2025 Non-covered Recipient Entity
Cancer And Hematology Centers Of Western Michigan, Pc
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184304885
Principal investigator 1 Ipsen Pharma SAS $2,300.00 05/19/2025 Non-covered Recipient Entity
Cancer And Hematology Centers Of Western Michigan, Pc
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184304887
Principal investigator 1 Ipsen Pharma SAS $13,250.00 05/19/2025 Non-covered Recipient Entity
Cancer And Hematology Centers Of Western Michigan, Pc
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184304889
Principal investigator 1 Ipsen Pharma SAS $3,700.00 05/19/2025 Non-covered Recipient Entity
Cancer And Hematology Centers Of Western Michigan, Pc
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184304891
Principal investigator 1 Ipsen Pharma SAS $1,642.00 05/19/2025 Non-covered Recipient Entity
Cancer And Hematology Centers Of Western Michigan, Pc
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184304893
Principal investigator 1 Ipsen Pharma SAS $4,032.00 05/19/2025 Non-covered Recipient Entity
Cancer And Hematology Centers Of Western Michigan, Pc
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184304895
Principal investigator 1 Ipsen Pharma SAS $3,950.00 05/19/2025 Non-covered Recipient Entity
Cancer And Hematology Centers Of Western Michigan, Pc
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184304897
Principal investigator 1 Ipsen Pharma SAS $5,154.00 05/19/2025 Non-covered Recipient Entity
Cancer And Hematology Centers Of Western Michigan, Pc
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184304899
Principal investigator 1 Ipsen Pharma SAS $2,000.00 05/19/2025 Non-covered Recipient Entity
Cancer And Hematology Centers Of Western Michigan, Pc
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184304901
Principal investigator 1 Ipsen Pharma SAS $2,926.00 05/19/2025 Non-covered Recipient Entity
Cancer And Hematology Centers Of Western Michigan, Pc
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184304903
Principal investigator 1 Ipsen Pharma SAS $3,200.00 05/19/2025 Non-covered Recipient Entity
Cancer And Hematology Centers Of Western Michigan, Pc
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184304905
Principal investigator 1 PFIZER INC. $1,622.51 05/19/2025 Non-covered Recipient Entity
START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840258
Principal investigator 1 PFIZER INC. $262.00 05/17/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228856220
Principal investigator 1 Genmab U.S., Inc. $220.00 05/15/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235935096
Principal investigator 1 PFIZER INC. $4,642.42 05/15/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228855318
Principal investigator 1 PFIZER INC. $1,996.65 05/14/2025 Non-covered Recipient Entity
START Midwest LLC
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228855349
Principal investigator 1 Genmab U.S., Inc. $89,000.12 05/12/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935514
Principal investigator 1 ABBVIE INC. $1,870.00 05/08/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202484175
Principal investigator 1 PFIZER INC. $12,958.24 05/06/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228855202
Principal investigator 1 PFIZER INC. $39,707.55 05/06/2025 Non-covered Recipient Entity
South Texas Accelerated Research TherapeuticsLLC
FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228855207
Principal investigator 1 PFIZER INC. $2,581.20 05/06/2025 Non-covered Recipient Entity
START Midwest LLC
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228855450
Principal investigator 1 ABBVIE INC. $9,822.00 05/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202481051
Principal investigator 1 ABBVIE INC. $935.00 05/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202481053
Principal investigator 1 ABBVIE INC. $300.00 05/02/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480909
Principal investigator 1 ABBVIE INC. $1,050.00 05/02/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480911
Principal investigator 1 ABBVIE INC. $450.00 05/02/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480913
Principal investigator 1 ABBVIE INC. $1,400.00 05/02/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480915
Principal investigator 1 ABBVIE INC. $1,750.00 05/02/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480917
Principal investigator 1 ABBVIE INC. $550.00 05/02/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480919
Principal investigator 1 ABBVIE INC. $50.00 05/02/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480921
Principal investigator 1 ABBVIE INC. $2,813.27 04/30/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480395
Principal investigator 1 ABBVIE INC. $2,589.84 04/30/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480405
Principal investigator 1 ABBVIE INC. $364.50 04/30/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480407
Principal investigator 1 ABBVIE INC. $2,589.84 04/30/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480409
Principal investigator 1 Genmab U.S., Inc. $1,559.79 04/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935462
Principal investigator 1 PFIZER INC. $7.50 04/28/2025 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840180
Principal investigator 1 PFIZER INC. $1,622.51 04/28/2025 Non-covered Recipient Entity
START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840252
Principal investigator 1 PFIZER INC. $3,245.02 04/28/2025 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840312
Principal investigator 1 PFIZER INC. $8,885.70 04/24/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228854571
Principal investigator 1 ABBVIE INC. $29,166.75 04/18/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202478146
Principal investigator 1 Stemline Therapeutics Inc. $53,195.00 04/18/2025 Non-covered Recipient Entity
START MIDWEST, LLC
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244134748
Principal investigator 1 Genmab U.S., Inc. $32,539.06 04/15/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935518
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $107,315.60 04/09/2025 Non-covered Recipient Entity
Start Midwest
A Phase 1/1b First- in -Human Trial of BMS-986484 as Monotherapy and in Combination Therapies in Participants with Advanced Solid Malignancies No dispute reported 06/30/2026 1235993467
Principal investigator 1 PFIZER INC. $630.70 04/08/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228860123
Principal investigator 1 PFIZER INC. $3,115.80 04/08/2025 Non-covered Recipient Entity
START Midwest LLC
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228860505
Principal investigator 1 ABBVIE INC. $1,788.75 04/07/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202474628
Principal investigator 1 ABBVIE INC. $270.00 04/07/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202474632
Principal investigator 1 ABBVIE INC. $1,998.00 04/07/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202474636
Principal investigator 1 ABBVIE INC. $270.00 04/07/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202474639
Principal investigator 1 ABBVIE INC. $2,338.20 04/07/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202474643
Principal investigator 1 ABBVIE INC. $270.00 04/07/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202474647
Principal investigator 1 PFIZER INC. $11,140.20 04/05/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228855161
Principal investigator 1 PFIZER INC. $251.78 04/05/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228856212
Principal investigator 1 Genmab U.S., Inc. $56,715.62 04/04/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235935150
Principal investigator 1 PFIZER INC. $13,177.35 04/01/2025 Non-covered Recipient Entity
START Midwest LLC
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228860113
Principal investigator 1 ABBVIE INC. $3,152.25 03/31/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467377
Principal investigator 1 ABBVIE INC. $3,253.50 03/31/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467382
Principal investigator 1 ABBVIE INC. $3,152.25 03/31/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467387
Principal investigator 1 ABBVIE INC. $3,152.25 03/31/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467391
Principal investigator 1 ABBVIE INC. $2,589.84 03/31/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467396
Principal investigator 1 ABBVIE INC. $2,589.84 03/31/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467412
Principal investigator 1 ABBVIE INC. $3,711.15 03/31/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467629
Principal investigator 1 ABBVIE INC. $2,157.84 03/31/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467633
Principal investigator 1 ABBVIE INC. $364.50 03/31/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467649
Principal investigator 1 ABBVIE INC. $3,711.15 03/31/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467654
Principal investigator 1 ABBVIE INC. $2,060.10 03/31/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467658
Principal investigator 1 ABBVIE INC. $364.50 03/31/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467661
Principal investigator 1 ABBVIE INC. $364.50 03/31/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467666
Principal investigator 1 ABBVIE INC. $2,813.27 03/31/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467670
Principal investigator 1 ABBVIE INC. $2,813.27 03/31/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467674
Principal investigator 1 ABBVIE INC. $3,711.15 03/31/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467685
Principal investigator 1 PFIZER INC. $3,245.02 03/31/2025 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840796
Principal investigator 1 PFIZER INC. $7.50 03/31/2025 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840882
Principal investigator 1 ABBVIE INC. $2,589.84 03/24/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465592
Principal investigator 1 ABBVIE INC. $2,589.84 03/24/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465597
Principal investigator 1 ABBVIE INC. $2,589.84 03/24/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465608
Principal investigator 1 ABBVIE INC. $2,589.84 03/24/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465611
Principal investigator 1 ABBVIE INC. $2,713.37 03/24/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465615
Principal investigator 1 ABBVIE INC. $2,813.27 03/24/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465621
Principal investigator 1 ABBVIE INC. $2,589.84 03/24/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465625
Principal investigator 1 ABBVIE INC. $2,063.34 03/24/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465629
Principal investigator 1 PFIZER INC. $1,622.51 03/24/2025 Non-covered Recipient Entity
START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840824
Principal investigator 1 PFIZER INC. $1,201.00 03/22/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL STUDY OF PF07934040 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING MUTATIONS IN THE KRAS GENE No dispute reported 06/30/2026 1228860572
Principal investigator 1 PFIZER INC. $1,307.48 03/22/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228860612
Principal investigator 1 PFIZER INC. $31,078.00 03/22/2025 Non-covered Recipient Entity
South Texas Accelerated Research TherapeuticsLLC
FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228862091
Principal investigator 1 PFIZER INC. $47,927.05 03/22/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228862121
Principal investigator 1 Genmab U.S., Inc. $16,898.00 03/21/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935446
Principal investigator 1 Genmab U.S., Inc. $3,500.00 03/21/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935451
Principal investigator 1 Genmab U.S., Inc. $17,300.00 03/21/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935454
Principal investigator 1 Genmab U.S., Inc. $26,514.00 03/21/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1235935458
Principal investigator 1 ABBVIE INC. $1,788.75 03/20/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465398
Principal investigator 1 ABBVIE INC. $270.00 03/20/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465402
Principal investigator 1 PFIZER INC. $20,917.27 03/14/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228862183
Principal investigator 1 PFIZER INC. $1,135.26 03/14/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228862325
Principal investigator 1 Merck Sharp & Dohme LLC $24,840.00 03/13/2025 Non-covered Recipient Entity
South Texas Accelerated Research Therapeutics START Midwest
A Phase 1,1b Dose Escalation,Expansion Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1232931906
Principal investigator 1 ABBVIE INC. $6,000.00 03/12/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202462907
Principal investigator 1 ABBVIE INC. $6,000.00 03/12/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202462911
Principal investigator 1 ABBVIE INC. $1,050.00 03/10/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202462233
Principal investigator 1 ABBVIE INC. $2,266.00 03/07/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202462130
Principal investigator 1 ABBVIE INC. $500.00 03/06/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202458967
Principal investigator 1 ABBVIE INC. $12,958.65 03/05/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202456227
Principal investigator 1 PFIZER INC. $1,480.95 03/04/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228862194
Principal investigator 1 PFIZER INC. $833.00 03/04/2025 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1228862317
Principal investigator 1 ABBVIE INC. $3,354.75 02/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202455118
Principal investigator 1 ABBVIE INC. $1,456.65 02/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202455122
Principal investigator 1 ABBVIE INC. $1,456.65 02/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202455126
Principal investigator 1 ABBVIE INC. $3,354.75 02/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202455129
Principal investigator 1 ABBVIE INC. $1,776.60 02/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202455134
Principal investigator 1 ABBVIE INC. $2,250.45 02/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202455148
Principal investigator 1 ABBVIE INC. $3,152.25 02/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202455151
Principal investigator 1 ABBVIE INC. $2,060.10 02/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202455156
Principal investigator 1 ABBVIE INC. $3,152.25 02/28/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202455294
Principal investigator 1 ABBVIE INC. $630.00 02/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202454829
Principal investigator 1 ABBVIE INC. $1,020.00 02/27/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202454841
Principal investigator 1 PFIZER INC. $42,534.45 02/25/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228836810
Principal investigator 1 PFIZER INC. $1,857.60 02/22/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL STUDY OF PF07934040 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING MUTATIONS IN THE KRAS GENE No dispute reported 06/30/2026 1228835330
Principal investigator 1 Genmab U.S., Inc. $55.00 02/20/2025 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235935072
Principal investigator 1 ABBVIE INC. $58,853.80 02/19/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202452535
Principal investigator 1 ABBVIE INC. $14,173.04 02/19/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202452539
Principal investigator 1 ABBVIE INC. $4,267.84 02/19/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202452550
Principal investigator 1 ABBVIE INC. $376.05 02/19/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202452554
Principal investigator 1 ABBVIE INC. $2,133.92 02/19/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202452558
Principal investigator 1 ABBVIE INC. $67.50 02/19/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202452587
Principal investigator 1 PFIZER INC. $3,245.02 02/19/2025 Non-covered Recipient Entity
START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840831
Principal investigator 1 PFIZER INC. $650.00 02/18/2025 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840789
Principal investigator 1 PFIZER INC. $6,490.04 02/18/2025 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840818
Principal investigator 1 PFIZER INC. $7.50 02/18/2025 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840874
Principal investigator 1 ABBVIE INC. $26,547.75 02/14/2025 Non-covered Recipient Entity
START MIDWEST LLC
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1202451996
Principal investigator 1 PFIZER INC. $1,996.65 02/14/2025 Non-covered Recipient Entity
START Midwest LLC
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228836632
Principal investigator 1 PFIZER INC. $39,176.40 02/14/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228836701
Recipient PFIZER INC. $330.00 02/11/2025 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228829093
Principal investigator 1 PFIZER INC. $4,192.00 02/05/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228835335
Principal investigator 1 PFIZER INC. $650.00 02/03/2025 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840165
Principal investigator 1 PFIZER INC. $7.50 02/03/2025 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840318
Principal investigator 1 ABBVIE INC. $8,722.89 01/30/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202443292
Principal investigator 1 ABBVIE INC. $6,401.75 01/30/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202443296
Principal investigator 1 ABBVIE INC. $5,817.15 01/30/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202443300
Principal investigator 1 ABBVIE INC. $11,630.52 01/30/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202443303
Principal investigator 1 ABBVIE INC. $490.05 01/30/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202443309
Principal investigator 1 ABBVIE INC. $6,776.19 01/30/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202443314
Principal investigator 1 ABBVIE INC. $500.85 01/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442068
Principal investigator 1 ABBVIE INC. $1,776.60 01/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442579
Principal investigator 1 ABBVIE INC. $1,456.65 01/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442583
Principal investigator 1 ABBVIE INC. $202.50 01/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442589
Principal investigator 1 ABBVIE INC. $2,589.84 01/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442633
Principal investigator 1 ABBVIE INC. $2,351.70 01/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442652
Principal investigator 1 ABBVIE INC. $3,354.75 01/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442655
Principal investigator 1 ABBVIE INC. $2,589.84 01/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442659
Principal investigator 1 ABBVIE INC. $364.50 01/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442665
Principal investigator 1 ABBVIE INC. $2,813.27 01/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442693
Principal investigator 1 ABBVIE INC. $3,354.75 01/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442697
Principal investigator 1 ABBVIE INC. $3,354.75 01/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442719
Principal investigator 1 ABBVIE INC. $2,934.77 01/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442722
Principal investigator 1 ABBVIE INC. $2,813.27 01/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442737
Principal investigator 1 ABBVIE INC. $2,138.27 01/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442741
Principal investigator 1 ABBVIE INC. $3,152.25 01/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442745
Principal investigator 1 ABBVIE INC. $2,060.10 01/29/2025 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442806
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,588.95 01/29/2025 Non-covered Recipient Entity
CANCER AND HEMATOLOGY CENTERS OF WESTERN MICHIGAN, PC
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation No dispute reported 06/30/2026 1185541744
Principal investigator 1 Ipsen Pharma SAS $70.00 01/28/2025 Non-covered Recipient Entity
Cancer And Hematology Centers Of Western Michigan, Pc
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304923
Principal investigator 1 Ipsen Pharma SAS $60.00 01/28/2025 Non-covered Recipient Entity
Cancer And Hematology Centers Of Western Michigan, Pc
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184304925
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,796.18 01/27/2025 Non-covered Recipient Entity
Start Midwest
A Phase 1/1b First- in -Human Trial of BMS-986484 as Monotherapy and in Combination Therapies in Participants with Advanced Solid Malignancies No dispute reported 06/30/2026 1235993465
Principal investigator 1 PFIZER INC. $12,718.00 01/23/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL STUDY OF PF07934040 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING MUTATIONS IN THE KRAS GENE No dispute reported 06/30/2026 1228861583
Principal investigator 1 PFIZER INC. $4,282.20 01/22/2025 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228860564
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $17,103.60 01/15/2025 Non-covered Recipient Entity
Start Midwest
A Phase 1b/2 Study of BMS-986442 in Combination with Nivolumab or Nivolumab and Chemotherapies in Participants with Advanced Solid Tumors and Non-small Cell Lung Cancer No dispute reported 06/30/2026 1235993461
Principal investigator 1 PFIZER INC. $1,996.65 01/15/2025 Non-covered Recipient Entity
START Midwest LLC
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228863198
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $9,412.21 01/10/2025 Non-covered Recipient Entity
Start Midwest
A Phase I/II First-in-human Study of BMS-986258 Alone and in Combination with Nivolumab in Advanced Malignant Tumors No dispute reported 06/30/2026 1235993463